These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20009920)

  • 1. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
    McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
    AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
    Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
    J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
    Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
    J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.
    McMahon MA; Siliciano JD; Lai J; Liu JO; Stivers JT; Siliciano RF; Kohli RM
    J Biol Chem; 2008 Nov; 283(46):31289-93. PubMed ID: 18818198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage protection against human immunodeficiency virus or herpes simplex virus by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and acyclovir.
    Rossi L; Brandi G; Schiavano GF; Balestra E; Millo E; Scarfi S; Damonte G; Gasparini A; Magnani M; Perno CF; Benatti U; De Flora A
    AIDS Res Hum Retroviruses; 1998 Mar; 14(5):435-44. PubMed ID: 9546803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
    Cahn P; Altclas J; Martins M; Losso M; Cassetti I; Cooper DA; Cox S
    HIV Med; 2011 Jul; 12(6):334-42. PubMed ID: 21054750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man.
    Henao-Martínez AF; Weinberg A; Waldman WJ; Levi ME
    J Clin Virol; 2012 Jul; 54(3):276-8. PubMed ID: 22465339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV).
    Arinze F; Shaver A; Raffanti S
    Infection; 2017 Oct; 45(5):705-707. PubMed ID: 28508238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
    Vanpouille C; Lisco A; Derudas M; Saba E; Grivel JC; Brichacek B; Scrimieri F; Schinazi R; Schols D; McGuigan C; Balzarini J; Margolis L
    J Infect Dis; 2010 Feb; 201(4):635-43. PubMed ID: 20085496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of a novel mutation conferring acyclovir resistance and consecutive treatment failure in an HIV-positive patient with recurrent HSV-2 infection.
    Schleenvoigt BT; Pletz MW; Deinhardt-Emmer S; Sauerbrei A
    J Glob Antimicrob Resist; 2018 Mar; 12():20. PubMed ID: 29179992
    [No Abstract]   [Full Text] [Related]  

  • 12. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient.
    Pardeiro M; Cuenca-Estrella M; Fernández-Clúa MA; Santos-O'Connor F; Tabarés E; Gadea I
    J Med Virol; 2004 May; 73(1):60-4. PubMed ID: 15042649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
    Kuritzkes DR
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
    [No Abstract]   [Full Text] [Related]  

  • 15. Phosphoramidate derivatives of acyclovir: synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro.
    Zakirova NF; Shipitsyn AV; Jasko MV; Prokofjeva MM; Andronova VL; Galegov GA; Prassolov VS; Kochetkov SN
    Bioorg Med Chem; 2012 Oct; 20(19):5802-9. PubMed ID: 22954898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase.
    Tchesnokov EP; Obikhod A; Massud I; Lisco A; Vanpouille C; Brichacek B; Balzarini J; McGuigan C; Derudas M; Margolis L; Schinazi RF; Götte M
    J Biol Chem; 2009 Aug; 284(32):21496-504. PubMed ID: 19509419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
    Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
    Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
    Nikolenko GN; Svarovskaia ES; Delviks KA; Pathak VK
    J Virol; 2004 Aug; 78(16):8761-70. PubMed ID: 15280484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.